KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Improving Outcome of Selected Patients With Non-Resectable Hepatic Metastases From Colorectal Cancer With Liver Transplantation: A Prospective Parallel Trial (COLT trial).

Carlo Sposito, Filippo Pietrantonio, Marianna Maspero, Fabrizio Di Benedetto, Marco Vivarelli, Giuseppe Tisone, Luciano De Carlis, Renato Romagnoli, Salvatore Gruttadauria, Michele Colledan, Salvatore Agnes, Giuseppe Ettorre, Umberto Baccarani, Guido Torzilli, Stefano Di Sandro, Domenico Pinelli, Lucio Caccamo, Andrea Sartore Bianchi, Carlo Spreafico, Valter Torri, Vincenzo Mazzaferro

Clin Colorectal Cancer 22(2) 250-255

PMID36822922
PMCID-
DOI10.1016/j.clcc.2023.01.003
发表日期2023-02-23
摘要

摘要

BACKGROUND: Patients with unresectable Colorectal Liver Metastases (CLM) receiving palliative chemotherapy have a 5-year overall survival (OS) of less than 30%. Liver transplantation (LT) can improve OS up to 60%-83% (SECA-I and SECA-II trials). The aim of the study is to assess the efficacy of LT in liver-only metastatic CRC compared with a matched cohort of patients included in a phase III trial on triplet chemotherapy + antiEGFR. PATIENTS AND METHODS: The COLT trial is an investigator-driven, multicenter, non-randomized, open-label, controlled, prospective, parallel trial (ClinicalTrials.gov NCT03803436). Hyperselected patients with liver-limited unresectable CLM, RAS and BRAF wild-type and curatively removed primary colon cancer are included. The observed post-transplant outcomes will be prospectively compared 1:5 with those obtained in a matched cohort from the TRIPLETE trial (NCT03231722). RESULTS: Primary endpoint is to compare the 3 and 5-years OS of patients enrolled in the COLT trial with COLT-eligible population enrolled in the TRIPLETE trial. An expected gain in OS of 40% at 5-years is predicted for the COLT population (the expected OS at 5-years in COLT vs. TRIPLETE is 70% vs. 30%). Secondary endpoints are to compare the 5-years disease-free survival and to assess the safety of LT (Dindo-Clavien Classification and the Comprehensive Complication Index). CONCLUSION: LT offers the longest OS reported in selected patients with CLM. Improving the selection strategies can give patients a 5-year OS similar to other indications for LT and a better outcome than those undergoing chemotherapy alone.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。